# Novartis Type: Company (NVS) Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/novartis Canonical HTML page: https://getbiobrief.com/entity/novartis ## Timeline - **2028**: Keytruda Patent Expiry — Merck faces biosimilar competition for its top-selling immunotherapy drug. - **2028-01-01**: Keytruda Patent Cliff — Expected loss of exclusivity for Merck's top-selling cancer drug, Keytruda. - **2027**: TERN-701 Data Readout — Key clinical milestones for the leukemia candidate are expected to drive valuation. - **2026-Q4**: Data Review — Expected first quarterly report on screening uptake and identification rates in Scotland. - **2026-Q3**: Part 2 Expansion — Full global enrollment for efficacy endpoints (rPFS and OS) expected to accelerate. - **2026-Q3**: Expected Closing — The deal is anticipated to close following regulatory approvals and Terns shareholder vote. - **2026-03-25**: Acquisition Announced — Merck and Terns Pharmaceuticals sign a definitive agreement for a $6.7B buyout. - **2026-03-25**: Terns Acquisition Announced — Merck agrees to buy Terns Pharmaceuticals for $6.7 billion to acquire TERN-701. - **2026-03-17**: Q4 2025 Earnings — Reported year-end financial results and updated 2027 cash runway. - **2026-03-10**: Primary Objectives Met — Telix announces Part 1 achieved all primary safety and dosimetry goals. - **2026-03**: Q4 2025 Earnings — Both companies report full-year 2025 results and 2026 guidance. - **2026-03**: Scotland Launch — Scotland officially begins nationwide screening for all newborns. - **2026-02-27**: Novartis Settlement — Novartis announces a confidential settlement with the Henrietta Lacks estate. - **2026**: Anticipated Milestone — Expected Phase 1 data readout for MRT-6160 in autoimmune diseases. - **2025-Q4**: Part 1 Completion — Enrollment for the safety and dosimetry portion of the study concludes. ## Recent coverage (10 stories) ### Alport Syndrome Market to Hit 47% CAGR Through 2036 on Gene Therapy Pipeline 2026-07-27 09:04:39 · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2 A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors. Full story: https://getbiobrief.com/story/alport-syndrome-market-47-cagr-2036-bio ### Novartis, Roche Face 50% PBS Price Cut on MS Drugs as Briumvi Triggers Review 2026-07-15 21:43:22 · Sentiment: Negative · Impact: 7/10 · Sources: 11 A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal. Full story: https://getbiobrief.com/story/pbs-ms-review-pharma ### Merck to Acquire Terns Pharmaceuticals for $6.7B to Bolster Oncology Pipeline 2026-03-25 19:18:13 · Sentiment: Positive · Impact: 8/10 · Sources: 2 Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda. Full story: https://getbiobrief.com/story/merck-terns-pharmaceuticals-acquisition-6-7b ### Merck to Acquire Terns for $6.7B to Mitigate Keytruda Patent Cliff 2026-03-25 16:35:08 · Sentiment: Positive · Impact: 8/10 · Sources: 2 Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda. Full story: https://getbiobrief.com/story/merck-terns-acquisition-oncology-strategy ### Scotland Becomes First UK Nation to Launch Newborn SMA Screening Program 2026-03-23 02:11:02 · Sentiment: Positive · Impact: 6/10 · Sources: 2 Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for Spinal Muscular Atrophy (SMA). This landmark public health initiative aims to identify the rare genetic condition within days of birth, enabling immediate access to life-saving gene therapies before irreversible muscle wasting occurs. Full story: https://getbiobrief.com/story/scotland-first-uk-newborn-sma-screening ### Monte Rosa Therapeutics Leverages Novartis Deal to Extend Runway into 2027 2026-03-19 14:20:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Monte Rosa Therapeutics reported quarterly results highlighting a robust cash position following its $2.1 billion Novartis partnership. The company is accelerating its molecular glue degrader pipeline with a strategic pivot toward high-value immunology indications. Full story: https://getbiobrief.com/story/monte-rosa-therapeutics-earnings-analysis-2026 ### Telix Pharmaceuticals Hits Key Milestone in Phase 3 Prostate Cancer Trial 2026-03-10 00:58:12 · Sentiment: Positive · Impact: 7/10 · Sources: 4 Telix Pharmaceuticals has announced that Part 1 of its ProstACT GLOBAL Phase 3 study for TLX591 successfully met its primary objectives. This milestone confirms the safety and dosimetry of the company's lead radiopharmaceutical candidate for metastatic prostate cancer, clearing the way for full trial expansion. Full story: https://getbiobrief.com/story/prostact-phase-3-primary-objectives-achieved ### Voyager and Zevra Set for Q4 Earnings Amid Commercial and Pipeline Shifts 2026-03-08 22:53:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment. Full story: https://getbiobrief.com/story/voyager-zevra-q4-2025-earnings-preview ### Novartis Settles With Henrietta Lacks Estate Over HeLa Cell Usage 2026-02-27 01:28:17 · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Novartis has reached a confidential settlement with the estate of Henrietta Lacks, ending litigation over the unauthorized use of her 'immortal' HeLa cells. This marks the latest in a series of legal victories for the Lacks family against pharmaceutical giants that profited from cells taken without consent in 1951. Full story: https://getbiobrief.com/story/novartis-settles-henrietta-lacks-hela-lawsuit ### JIA Market to Reach $2.3B as Biologic Innovation Drives 5.6% CAGR through 2036 2026-02-19 02:07:52 · Sentiment: Positive · Impact: 6/10 · Sources: 4 The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036. Full story: https://getbiobrief.com/story/juvenile-idiopathic-arthritis-market-growth-2036 --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.